Post by
westcoast1000 on Feb 06, 2023 6:08pm
90 day period question
Do any readers know whether Roche has early access to the Pfizer trial data during the 90 day hold period before releasing the HR 2 neg BC data?
Comment by
Buckhenry on Feb 06, 2023 6:26pm
you folks are getting into it over something that you are speculating and know very little about. just take a chill pill and a bag of popcorn and sit back and relax. however it is funny that unnoteable gets down right nasty if you dont agree with him... keep it up... love it.
Comment by
westcoast1000 on Feb 06, 2023 6:42pm
The reason I asked the question below is because Roche may not be in an informed position to make an offer without that data. From below: Do any readers know whether Roche has early access to the Pfizer trial data during the 90 day hold period before releasing the HR 2 neg BC data?
Comment by
Noteable on Feb 06, 2023 6:53pm
Correct westcoast. Roche would like to see the data, particularly since Roche has already stated that it is counting on Tecentriq (atezolizumab) to deliver significant revenues for the company going forward. Pfizer/Merck KGaA have "first mover advantage" in this case.
Comment by
fox7mf on Feb 06, 2023 7:11pm
That 'right of first refusal', or 'first mover advantage', or exclusivity for PFE on Bracelet-1 is days away from ending. Expect a move soon. Perhaps a bidding war is already at hand.
Comment by
Noteable on Feb 06, 2023 6:45pm
No. Only Pfizer and Merck KGaA have "exclusivity" to the Bracelet-1 Phase 2 breast cancer study data.